Skip to main content
SpringerLink
Log in

Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice

  • Original Paper
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract

The biochemical and cellular changes that occur following the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are remarkably similar to that seen in idiopathic Parkinson’s disease(PD). There is growing evidence indicating that reactive oxygen species (ROS), reactive nitrogen species (RNS) and inflammation are a major contributor to the pathogenesis and progression of PD. Hence, we investigated whether 7-nitroindazole [neuronal nitric oxide synthase (nNOS) inhibitor], edaravone (free radical scavenger), minocycline [inducible NOS (iNOS) inhibitor], fluvastatin [endothelial NOS (eNOS) activator], pitavastatin (eNOS activator), etodolac [cyclooxygenase-2 (COX-2) inhibitor] and indomethacin (COX inhibitor) can protect against MPTP neurotoxicity in mice under the same conditions. For the evaluation of each drug, the levels of dopamine, DOPAC and HVA were quantified using HPLC with an electrochemical detector. Four administrations of MPTP at 1-h intervals to mice produced marked depletion of dopamine, DOPAC (3,4-dihydroxyphenylacetic acid) and HVA (homovanilic acid) in the striatum after 5days. 7-Nitroindazole prevented dose-dependently a significant reduction in dopamine contents of the striatum 5days after MPTP treatment. In contrast, edaravone, minocycline, fluvastatin, pitavastatin, etodolac and indomethacin did not show the neuroprotective effect on MPTP-induced striatal dopamine, DOPAC and HVA depletions after 5days. The present study demonstrates that the overexpression of nNOS may play a major role in the neurotoxic processes of MPTP, as compared with the production of ROS, the overexpression of iNOS, the modulation of eNOS and the involvement of inflammatory response. Thus our pharmacological findings provide further information for progressive neurodegeneration of the nigrostriatal dopaminergic neuronal pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  • Agid Y (1991) Parkinson’s disease: pathophysiology. Lancet 337:1321–1324

    Article  PubMed  CAS  Google Scholar 

  • Araki T, Tanji H, Fujihara K, Kato H, Itoyama Y (1999) Increases in [3H]FK-506 and [3H]L-NG-nitro-arginine binding in the rat brain after nigrostriatal dopaminergic denervation. Metab Brain Dis 14:21–31

    Article  PubMed  CAS  Google Scholar 

  • Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y (2001) Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci 12:231–238

    Article  PubMed  CAS  Google Scholar 

  • Bauer MK, Lieb K, Schulze-Osthoff K, Berger M, Gebicke-Haerter PJ, Bauer J, Fiebich BL (1997) Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem 243:726–731

    Article  PubMed  CAS  Google Scholar 

  • Beal MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson’s disease. Ann NY Acad Sci 991:120–131

    Article  PubMed  CAS  Google Scholar 

  • Beckman JS, Beckman TW, Chen J (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 87:1620–1624

    Article  PubMed  CAS  Google Scholar 

  • Beckman JS, Ischiropoulos H, Zhu L (1992) Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys 298:438–445

    Article  PubMed  CAS  Google Scholar 

  • Bernheimer H, Birkmayer W, Hornykeiwicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455

    Article  PubMed  CAS  Google Scholar 

  • Bredt DS, Snyder SH (1990) Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A 87:682–685

    Article  PubMed  CAS  Google Scholar 

  • Bredt DS, Snyder SH (1994) Nitric oxide: a physiologic messenger molecule. Ann Rev Biochem 63:175–195

    Article  PubMed  CAS  Google Scholar 

  • Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem 82:615–624

    Article  PubMed  CAS  Google Scholar 

  • Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909

    Article  PubMed  CAS  Google Scholar 

  • Dawson TM, Snyder SH (1994) Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J Neurosci 14:5147–5159

    PubMed  CAS  Google Scholar 

  • Dawson VL, Dawson TM, London ED, Bredit DS, Snyder SH (1991) Nitric oxide mediates glutamate neurotoxicity in primary cultures. Proc Natl Acad Sci U S A 88:6268–6371

    Google Scholar 

  • Dehmer T, Lindenau J, Haid S, Dichgans J, Schultz JB (2000) Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74:2213–2216

    Article  PubMed  CAS  Google Scholar 

  • Di Monte DA, Royland JE, Anderson A, Castagnoli K, Castagoli Jr N , Langston JW (1997) Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity. J Neurochem 69:1771–1773

    Article  PubMed  Google Scholar 

  • Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 95:8880–8885

    Article  PubMed  CAS  Google Scholar 

  • Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R, Hong JS (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4- phenyl-,2,3,6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329:354–358

    Article  PubMed  CAS  Google Scholar 

  • Hantraye P, Brouillet E, Ferrante R, Pafi S, Dolan R, Matthews RT, Beal MF (1996) Inhibition of neuronal nitric oxide synthase prevents MPTP-induced Parkinsonism in baboons. Nat Med 2:1017–1021

    Article  PubMed  CAS  Google Scholar 

  • Hasegawa E, Takeshige K, Oishi T, Murai Y, Minakami S (1990) 1-Methylphenylpyridinium (MPP+) induces NADH-dependent superoxideformation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 170:1049–1055

    Article  PubMed  CAS  Google Scholar 

  • Hirsh E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334:345–348

    Article  Google Scholar 

  • Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson’s disease. Ann NY Acad Sci 991:214–228

    Article  PubMed  CAS  Google Scholar 

  • Hurley SD, O'Banion MK, Song DD, Arana FS, Olschowka JA, Haber SN (2003) Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP-administration in monkeys. Exp Neurol 184:659–668

    Article  PubMed  CAS  Google Scholar 

  • Ignarro LJ (1990) Biosynthesis and metabolism of endothelium-derived nitric oxide. Ann Rev Pharmacol Toxicol 30:535–560

    Article  CAS  Google Scholar 

  • Ischiropoulos H, Zhu L, Chen J (1992) Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 298:431–437

    Article  PubMed  CAS  Google Scholar 

  • Kurosaki R, Akasak M, Michimata M, Matsubara M, Ima Y, Araki T (2003) Effects of Ca2+ antagonists on motor activity and the dopaminergic system in aged mice. Neurobiol Aging 24:315–319

    Article  PubMed  CAS  Google Scholar 

  • Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeration in the MPTP model of Parkinson disease. Nat Med 5:1403–1409

    Article  PubMed  CAS  Google Scholar 

  • Lonart G, Johanson KM (1992) Inhibitory effects of nitric oxide on the uptake of [3H]dopamine and [3H]glutamate by striatal synaptosomes. J Neurochem 63:2108–2117

    Article  Google Scholar 

  • Marletta MA (1994) Nitric oxide synthase: aspects concerning structure and catalysis. Cell 78:927–930

    Article  PubMed  CAS  Google Scholar 

  • McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia and positive for HLS-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291

    PubMed  CAS  Google Scholar 

  • Minghetti L, Walsh DT, Levi G, Perry VH (1999) In vivo expression of cyclooxygenase-2 in rat brain following intraparenchymal injection of bacterial endotoxin and inflammatory cytokines. J Neuropathol Exp Neurol 58:1184–1191

    Article  PubMed  CAS  Google Scholar 

  • Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43:109–142

    PubMed  CAS  Google Scholar 

  • Muramatsu Y, Kurosaki R, Watanabe H, Michimata M, Matsubara M, Imai Y, Araki T (2003) Cerebral alterations in a MPTP-mouse model of Parkinson’s disease-an immunocytochemical study. J Neural Transm 110:1129–1144

    Article  PubMed  CAS  Google Scholar 

  • Murphy S, Simmons ML, Agullo L, Garcia A, Feinstein DL, Galea E, Reis DJ, Minc-Colomb D, Schwartz JP (1993) Synthesis of nitric oxide in CNS glial cells. Trends Neurosci 16:323–328

    Article  PubMed  CAS  Google Scholar 

  • Nathan C, Xie QW (1994) Nitric oxide synthases: roles, tolls, and controls. Cell 78:915–918

    Article  PubMed  CAS  Google Scholar 

  • O’Banion MK (1999) COX-2 and Alzheimer’s disease: potential roles in inflammation and neurodegeneration. Expert Opin Invest Drugs 8:1521–1536

    Article  Google Scholar 

  • Pasinetti GM (1998) Cyclooxygenase and inflammation in Alzheimer’s disease: experimental approaches and clinical interventions. J Neurosci Res 54:1–6

    Article  PubMed  CAS  Google Scholar 

  • Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR (2003) Neuroprotective agents for clinical trials in Parkinson’s disease: a systematic assessment. Neurology 60:1234–1240

    PubMed  CAS  Google Scholar 

  • Rice-Evans CA (1994) Formation of free radicals and mechanisms of action in normal biochemical processes and pathological states. In: Rice-Evans CA, Burdon RH (eds) Free radical damage and its control. Elsevier, Amsterdam, pp 131–153

    Chapter  Google Scholar 

  • Samuelsson B (1991) Arachidonic acid metabolism: role in inflammation. Z Rheumatol Suppl 50:3–6

    Google Scholar 

  • Schulz JB, Matthews RT, Muqit MMK (1995) Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 64:936–939

    Article  PubMed  CAS  Google Scholar 

  • Selley ML (2005) Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 1037:1–6

    Article  PubMed  CAS  Google Scholar 

  • Smith WL, DeWitt DL, Garavitro RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145–182

    Article  PubMed  CAS  Google Scholar 

  • Sriram K, Pai KS, Boyd MR, Ravindranath V (1997) Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res 749:44–52

    Article  PubMed  CAS  Google Scholar 

  • Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S (2003) Cyclooxygenase-2 is instrumental in Parkinson’s disease. Proc Natl Acad Sci U S A 100:5473–5478

    Article  PubMed  CAS  Google Scholar 

  • Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191–1206

    Article  PubMed  CAS  Google Scholar 

  • Watanabe Y, Kato H, Araki T (2008) Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson’s disease. Metab Brain Dis 23:51–69

    Article  PubMed  CAS  Google Scholar 

  • Wenzel SE (1997) Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 17:3S–12S

    PubMed  CAS  Google Scholar 

  • Wu DC, Jakson-Lewis M, Vila M, Tieu K, Teismann C, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763–1771

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurobiology and Therapeutics, Graduate School and Faculty of Pharmaceutical Sciences, The University of Tokushima, 1–78, Sho-machi, Tokushima, 770-8505, Japan

    Hironori Yokoyama, Ryohei Yano, Eriko Aoki & Tsutomu Araki

  2. Department of Neurology, Organized Center of Clinical Medicine, International University of Health and Welfare, Tochigi, Japan

    Hiroyuki Kato

Authors
  1. Hironori Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryohei Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eriko Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroyuki Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tsutomu Araki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsutomu Araki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yokoyama, H., Yano, R., Aoki, E. et al. Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice. Metab Brain Dis 23, 335–349 (2008). https://doi.org/10.1007/s11011-008-9096-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11011-008-9096-3

Keywords

Search

Navigation